SlideShare uma empresa Scribd logo
1 de 26
Baixar para ler offline
DIABETIC MACULAR
EDEMA & ITS
MANAGEMENT
PRESENTED BY: NIGAR MEHTIYEVA, 10TH SEMESTER,
FACULTY OF MEDICINE.
UNIVERSITY: TBILISI STATE MEDICAL UNIVERSITY,
GEORGIA.
Guided by Nino Karanadze, Lions Eye Diabetes Clinic
INTRODUCTION
• Diabetic macular edema (DME) is a serious complication of
diabetes that affects the eyes.
• It occurs when the blood vessels in the retina, the part of the eye
that senses light and sends images to the brain, become damaged
due to high blood sugar levels.
• This damage can cause fluid to leak into the macula, the central
part of the retina responsible for sharp, detailed vision.
• DME can cause vision loss and can make it difficult to read, drive,
or recognize faces.
• It is a common cause of vision loss in people with diabetes and
can occur at any stage of the disease, although it is more common
in people with advanced stages of diabetic retinopathy
• Early detection and treatment are important in managing DME and
preventing vision loss
DIABETES PREVALENCE in UAE
• The UAE has a high prevalence of diabetes, with
rates of 16.3% for adults aged 20-79 years according
to IDF statistics in 2019.
• A survey from 1999-2000 found a similar rate of
20.0% for those aged 20-64 years using OGTT.
• More recent data from the Weqaya screening
program in Abu Dhabi for 2008-2010 found age-
standardized prevalence rates of 17.6% for diabetes
and 27.1% for pre-diabetes.
• However, there have been few studies on diabetes
prevalence in the UAE since then.
• A recent research conducted in the Northern Emirates of the
UAE discovered that the rate of diabetes was 25.1% among its
citizens.
• The prevalence of diabetes was found to be higher in UAE
citizens, ranging from 25% as compared to 13-19% in
expatriates.
• The study also revealed that the rate of diabetes increased with
age and reached a maximum of 40% in people over 55 years of
age.
• The prevalence of impaired fasting glycemia was observed to
be 5% in men and 7% in women.
• Shockingly, the survey also found that 41% of individuals with
diabetes were previously undiagnosed.
• Obesity was also found to be common in all ethnic groups in
the study
RISK FACTORS FOR OBESITY/DIABETES IN
UAE
• The swift urbanization and socioeconomic advancement
in the UAE have resulted in the local population's
extensive adoption of a sedentary lifestyle and
Westernized diet, contributing to the risk factors for
obesity and diabetes.
• These risk factors are also linked with increasing waist-
hip ratio (WHR), age, systolic blood pressure, and
ethnicity.
• Additionally, the survey found that co-morbidity with
glucose intolerance occurred in 8% of individuals with
obesity and with hypertension in 5%
OCULAR COMPLICATIONS OF DIABETES:
• These conditions include
• diabetic retinopathy,
• diabetic macular edema,
• cataracts,
• glaucoma,
• poor vision,
• diabetes
PREVALENCE..
• Diabetic eye diseases make up 2 of the top 5 eye
problems affecting UAE patients
• Diabetic retinopathy and Diabetic Macular Edema (DME)
are two of the top five eye problems affecting UAE
patients
• One study found prevalence of retinopathy to be 19 per
cent in the UAE and was more likely to occur in older
males
• A collaboration between the Emirates Society of
Ophthalmology and a committee consisting of
specialized ophthalmologists in Retina, SEHA, Dubai
Health Authority, Ministry of Health, and private hospitals
in the UAE was formed to work on the Diabetic Macular
Edema Management Consensus
SCREENING
• Bayer ME & Emirates Ophthalmology Society launched "Eyes
On" campaign to tackle Diabetic Macular Edema in UAE.
• Campaign aims to raise awareness among diabetic patients
about the serious implications of DME.
• Retinal department at SEHA focuses on conditions at the
back of the eye, including diabetic eye screening.
• Primary care facilities in UAE offer screening programs for
DME.
• Patients urged to have their eyes examined as soon as they
are diagnosed with diabetes, as Diabetic Retinopathy can
already be present in some cases.
Introduction on ESO
• ESO has taken on the responsibility of overseeing and
organizing scientific training, conferences, and events while
also collaborating with health organizations.
• It is considered the leading Society for Ophthalmology in the
GCC area, not just in the UAE.
• The society aims to promote Continuous Professional
Development, facilitate the exchange of scientific information,
and encourage research and development in Ophthalmology.
• ESO has developed these guidelines with the objective
of offering clinical recommendations that are based on
evidence, for the optimal management of various
aspects of diabetic eye disease.
• The guidelines have been created with a specific focus
on the management of Diabetic Macular Edema, and
have been designed to address cases of retinopathy that
pose a serious risk to vision.
Treatment Pre-requisites
• It is recommended to check Visual Acuity (VA) before
initiation of treatment
• recommended to check intraocular pressure (IOP)
before initiation of treatment
• OCT is recommended before the initiation of treatment,
• Ocular fundus exam is recommended
• Fundus Fluorescein Angiography (FFA)
WHEN SHOULD WE TREAT?
• The purpose of treating DME is to enhance vision when it
is impaired, preserve existing vision, and prevent any
structural harm to the macula.
• It is essential to conduct a thorough evaluation of the
macula's structure and function to achieve this goal
• Conditions which are needed to initiate treatment:
• Best Corrected Visual Acuity (BCVA) of 20/30 or below, and/or
the presence of DME features as observed on OCT, with a
Central Retinal Thickness (CRT) of 300 microns or more
(≥300 μm).
• Patients experiencing symptoms with vision better than
20/25(13) and /or CRT<300 μm(12,13) with OCT features
indicative of center-involving macular edema should be
treated.
General Guidance in DME Management
• Good control of Diabetes Mellitus and HbA1c, arterial
hypertension, dyslipidemia, and quitting smoking is crucial for
managing DME.
• Achieving a normal BMI through weight loss is important
• Manage renal impairment, sleep apnea, and other relevant
conditions in consultation with a diabetologist
• Fenofibrate and statin can be recommended to the family
physicians / endocrinologists as anti-dyslipidemia medication
• Investigate other potential ocular causes of decreased vision.
• Monitor for any new medications or changes in medication that
could exacerbate macular edema, such as Glitazones
• Conduct FFA/OCTA to evaluate macular ischemia in
case of no improvement in visual acuity
• Use anti-VEGF injections or Dexamethasone Implant to
reduce macular thickness
• Discuss all ophthalmic treatment options with the patient
• Improve compliance and set realistic expectations
• All ophthalmic treatment options should be discussed
with the patient for better compliance and expectations
Tx Recommendation for Non-Centre Involving DME
• Observation may be the initial approach for Non-Center Involving
DME
• Anti-VEGF therapy or FFA-guided focal laser may be recommended
if there is progression towards the center
• Avoid treatment closer than 300-500 μm from the center of the
macula
• Focal Laser should only be performed by a retina specialist in
special circumstances
Treatment Recommendation for Centre Involving DME
• Anti-VEGF therapy is the first-line treatment
option for Centre-Involving DME (CI-DME)
• Steroid implant (Dexamethasone implant) may be
used as a first-line treatment if anti-VEGF therapy
is not recommended or if the patient is poorly
compliant
• Regular follow-up is required to monitor
intraocular pressure (IOP)
• Dexamethasone implant may be suggested for
vitrectomized, pseudophakic, or chronic DME
patients
• Treatment algorithms may vary based on patient
and physician preferences.
• Fixed, pro re nata (PRN), and treat-and-extend dosing
strategies can be considered for treating DME
• All patients treated with anti-VEGF should have a
loading dose of 3-5 injections
• Estimated number of injections is 8-9 in the first year and
5-6 in the second year, including the loading dose
• Dosing strategies based on VA and OCT response
Anti-VEGF Contraindications
• Avoid anti-VEGF treatment for at least 3 months after
myocardial infarction or stroke
• Anti-VEGF treatment is not recommended during
pregnancy or breastfeeding
• Steroid can be considered as first-line treatment in
pregnancy or breastfeeding
• Intravitreal therapy for DME should be deferred in cases
of active infection
Relapsing DME(Edema After
1Year)
• If a patient experiences relapsing DME and there is clear
evidence of a response to a previous treatment, the
same treatment can be repeated.
• However, if there is no response, the patient should be
treated as a new case and any available treatment
option, such as anti-VEGF or a Dexamethasone implant,
should be considered.
Refractory DME
• Refractory DME is defined as DME not responding to a
full course of anti- VEGF agents and steroid implants.
• In such cases, we can consider ;
•
a combination therapy with anti-VEGF and steroids
• or
• referral to a retina surgeon for vitrectomy if OCT
confirms ERM or VMT.
Steroid Implant
• Dexamethasone implant injections recommended: 3-4 within 12
months
• If good response and infrequent recurrence, continue with
Dexamethasone implant
• Effect of Dexamethasone implant peaks at 6-8 weeks and lasts up
to 4 months
• If frequent fluid recurrence, switch to Anti-VEGF after discussing
with patient
• If patient prefers not to receive implant every 4 months, consider
switching to Fluocinolone implant.
Contraindications of Dexamethasone and
fluocinolone acetonide intravitreal implants
• patients with active or suspected ocular or periocular
infection,
• advanced glaucoma requiring more than three
medications,
• non-intact posterior capsule (excluding YAG
capsulotomy),
• aphakia,
• or hypersensitivity to Dexamethasone implant
• or fluocinolone acetonide intravitreal implant should not
receive these treatments.
DME and PDR
• Initially assess VA, and do a fully dilated fundus exam.
• Anti-VEGF agents are the first-line treatment for centre-
involving DME.
• Anti-VEGF treatment or pan retinal photocoagulation (PRP)
can be considered for non-centre involving DME and PDR
• Combination of both treatments can be used for PDR
• Anti-VEGF injections can be continued for DME after PDR
treatment.
Diabetic Macular Edema and Pregnancy
• Control blood glucose and use laser treatment as first-line options for managing
DME during pregnancy
• Avoid anti-VEGF treatment for DME during pregnancy
• Intravitreal Dexamethasone implant can be considered for severe DME
• Laser treatment is a viable option for non-centre-involving Macular edema
• Treatment can be postponed until after delivery if feasible
• If treatment is offered during pregnancy, it should be done only in the second or
third trimesters
• Discuss potential risks of treatment with the patient, including elevated
intraocular pressure, cataract development, and rare risk of fetal harm.
reference
• https://www.ema.ae/chop/multimedia/userfiles/file/ICON
%20Publication.pdf
• https://insights.omnia-health.com/medical-
specialities/diabetic-eye-diseases-make-2-top-5-eye-
problems-affecting-uae-patients

Mais conteúdo relacionado

Semelhante a DIABETIC MACULAR EDEMA, ITS SCREENING IN UAE & MANAGEMENT STRATEGIES.pptx

Dr Somdutt Prasad On Diabetes & Blindness: An overview & key to overcome
Dr Somdutt Prasad On Diabetes & Blindness: An overview & key to overcomeDr Somdutt Prasad On Diabetes & Blindness: An overview & key to overcome
Dr Somdutt Prasad On Diabetes & Blindness: An overview & key to overcomedrsomduttprasad
 
Diabetic Retinopathy_Dr. Bastola.pptx
Diabetic Retinopathy_Dr. Bastola.pptxDiabetic Retinopathy_Dr. Bastola.pptx
Diabetic Retinopathy_Dr. Bastola.pptxDr. Pradeep Bastola
 
Dr Somdutt Prasad: Eye Donation Awareness
Dr Somdutt Prasad: Eye Donation AwarenessDr Somdutt Prasad: Eye Donation Awareness
Dr Somdutt Prasad: Eye Donation Awarenessdrsomduttprasad
 
Dr screening training for nurses 1-diabetic retinopathy screening programs,...
Dr screening training for nurses   1-diabetic retinopathy screening programs,...Dr screening training for nurses   1-diabetic retinopathy screening programs,...
Dr screening training for nurses 1-diabetic retinopathy screening programs,...Riyad Banayot
 
F14 aus diabetes &amp; your eyes
F14 aus diabetes &amp; your eyesF14 aus diabetes &amp; your eyes
F14 aus diabetes &amp; your eyesDiabetes for all
 
Central serous choroidopathy
Central serous choroidopathyCentral serous choroidopathy
Central serous choroidopathylalit22dag
 
Diabetic Macular Edema (Surgery presentation)
Diabetic Macular Edema (Surgery presentation)Diabetic Macular Edema (Surgery presentation)
Diabetic Macular Edema (Surgery presentation)Shabana2428
 
vi_psa_pres_common_eye_conditions_aug10.ppt
vi_psa_pres_common_eye_conditions_aug10.pptvi_psa_pres_common_eye_conditions_aug10.ppt
vi_psa_pres_common_eye_conditions_aug10.pptkevinguadilla
 
vi_psa_pres_common_eye_conditions_aug10.ppt
vi_psa_pres_common_eye_conditions_aug10.pptvi_psa_pres_common_eye_conditions_aug10.ppt
vi_psa_pres_common_eye_conditions_aug10.pptshahilagaz
 
Behcet disease (2)
Behcet disease (2)Behcet disease (2)
Behcet disease (2)Rajamarhamah
 
Medical management of glaucoma
Medical management of glaucomaMedical management of glaucoma
Medical management of glaucomaKumarSingh44
 
Eye health campaign workshop IFMSA
Eye health campaign workshop IFMSAEye health campaign workshop IFMSA
Eye health campaign workshop IFMSAMohamed Abdelmongy
 

Semelhante a DIABETIC MACULAR EDEMA, ITS SCREENING IN UAE & MANAGEMENT STRATEGIES.pptx (20)

Dr Somdutt Prasad On Diabetes & Blindness: An overview & key to overcome
Dr Somdutt Prasad On Diabetes & Blindness: An overview & key to overcomeDr Somdutt Prasad On Diabetes & Blindness: An overview & key to overcome
Dr Somdutt Prasad On Diabetes & Blindness: An overview & key to overcome
 
Diabetic Retinopathy_Dr. Bastola.pptx
Diabetic Retinopathy_Dr. Bastola.pptxDiabetic Retinopathy_Dr. Bastola.pptx
Diabetic Retinopathy_Dr. Bastola.pptx
 
Dr Somdutt Prasad: Eye Donation Awareness
Dr Somdutt Prasad: Eye Donation AwarenessDr Somdutt Prasad: Eye Donation Awareness
Dr Somdutt Prasad: Eye Donation Awareness
 
Preoperative evaluation for LASIK & PRK
Preoperative evaluation for LASIK & PRKPreoperative evaluation for LASIK & PRK
Preoperative evaluation for LASIK & PRK
 
Dr screening training for nurses 1-diabetic retinopathy screening programs,...
Dr screening training for nurses   1-diabetic retinopathy screening programs,...Dr screening training for nurses   1-diabetic retinopathy screening programs,...
Dr screening training for nurses 1-diabetic retinopathy screening programs,...
 
F14 aus diabetes &amp; your eyes
F14 aus diabetes &amp; your eyesF14 aus diabetes &amp; your eyes
F14 aus diabetes &amp; your eyes
 
Central serous choroidopathy
Central serous choroidopathyCentral serous choroidopathy
Central serous choroidopathy
 
Diabetic Macular Edema (Surgery presentation)
Diabetic Macular Edema (Surgery presentation)Diabetic Macular Edema (Surgery presentation)
Diabetic Macular Edema (Surgery presentation)
 
10. 2 disorders of retina
10. 2 disorders of retina10. 2 disorders of retina
10. 2 disorders of retina
 
Diabetic macula edema
Diabetic macula edemaDiabetic macula edema
Diabetic macula edema
 
vi_psa_pres_common_eye_conditions_aug10.ppt
vi_psa_pres_common_eye_conditions_aug10.pptvi_psa_pres_common_eye_conditions_aug10.ppt
vi_psa_pres_common_eye_conditions_aug10.ppt
 
vi_psa_pres_common_eye_conditions_aug10.ppt
vi_psa_pres_common_eye_conditions_aug10.pptvi_psa_pres_common_eye_conditions_aug10.ppt
vi_psa_pres_common_eye_conditions_aug10.ppt
 
Diabetic eye disease
Diabetic eye diseaseDiabetic eye disease
Diabetic eye disease
 
46191.ppt
46191.ppt46191.ppt
46191.ppt
 
46191.ppt
46191.ppt46191.ppt
46191.ppt
 
Diabetic retinopathy
Diabetic retinopathyDiabetic retinopathy
Diabetic retinopathy
 
Behcet disease (2)
Behcet disease (2)Behcet disease (2)
Behcet disease (2)
 
Medical management of glaucoma
Medical management of glaucomaMedical management of glaucoma
Medical management of glaucoma
 
Diabetic macular edema 2011 (1)
Diabetic macular edema 2011 (1)Diabetic macular edema 2011 (1)
Diabetic macular edema 2011 (1)
 
Eye health campaign workshop IFMSA
Eye health campaign workshop IFMSAEye health campaign workshop IFMSA
Eye health campaign workshop IFMSA
 

Último

Artificial Intelligence: Diabetes Management
Artificial Intelligence: Diabetes ManagementArtificial Intelligence: Diabetes Management
Artificial Intelligence: Diabetes ManagementIris Thiele Isip-Tan
 
21 NEMT Trends & Statistics to Know in 2024
21 NEMT Trends & Statistics to Know in 202421 NEMT Trends & Statistics to Know in 2024
21 NEMT Trends & Statistics to Know in 2024Traumasoft LLC
 
Artificial Intelligence in Healthcare: Challenges, Risks, Benefits
Artificial Intelligence in Healthcare: Challenges, Risks, BenefitsArtificial Intelligence in Healthcare: Challenges, Risks, Benefits
Artificial Intelligence in Healthcare: Challenges, Risks, BenefitsIris Thiele Isip-Tan
 
Anatomy Shelf Notevbhhhhhhhhhhhhhhhs.pdf
Anatomy Shelf Notevbhhhhhhhhhhhhhhhs.pdfAnatomy Shelf Notevbhhhhhhhhhhhhhhhs.pdf
Anatomy Shelf Notevbhhhhhhhhhhhhhhhs.pdfhezamzaki1
 
Diseases of the Respiratory System (J00-J99),.pptx
Diseases of the Respiratory System (J00-J99),.pptxDiseases of the Respiratory System (J00-J99),.pptx
Diseases of the Respiratory System (J00-J99),.pptxEMADABATHINI PRABHU TEJA
 
Three Keys to a Successful Margin: Charges, Costs, and Labor
Three Keys to a Successful Margin: Charges, Costs, and LaborThree Keys to a Successful Margin: Charges, Costs, and Labor
Three Keys to a Successful Margin: Charges, Costs, and LaborHealth Catalyst
 
ACCA Version of AI & Healthcare: An Overview for the Curious
ACCA Version of AI & Healthcare: An Overview for the CuriousACCA Version of AI & Healthcare: An Overview for the Curious
ACCA Version of AI & Healthcare: An Overview for the CuriousKR_Barker
 
Hematinics and Erythropoietin- Pharmacology of Hematinics
Hematinics and Erythropoietin- Pharmacology of HematinicsHematinics and Erythropoietin- Pharmacology of Hematinics
Hematinics and Erythropoietin- Pharmacology of Hematinicsnetraangadi2
 
Understanding Warts and Moles: Differences, Types, and Common Locations
Understanding Warts and Moles: Differences, Types, and Common LocationsUnderstanding Warts and Moles: Differences, Types, and Common Locations
Understanding Warts and Moles: Differences, Types, and Common LocationsNeha Sharma
 
CECT NECK NECK ANGIOGRAPHY CAROTID ANGIOGRAPHY
CECT NECK NECK ANGIOGRAPHY CAROTID ANGIOGRAPHYCECT NECK NECK ANGIOGRAPHY CAROTID ANGIOGRAPHY
CECT NECK NECK ANGIOGRAPHY CAROTID ANGIOGRAPHYRMC
 
Toothpaste for bleeding gums and sensitive teeth. Teeth whitening, Mouthwash....
Toothpaste for bleeding gums and sensitive teeth. Teeth whitening, Mouthwash....Toothpaste for bleeding gums and sensitive teeth. Teeth whitening, Mouthwash....
Toothpaste for bleeding gums and sensitive teeth. Teeth whitening, Mouthwash....sharyurangari111
 
NEONATAL RESPIRATORY CARE FROM A PHYSIO POV.pptx
NEONATAL RESPIRATORY CARE FROM A PHYSIO POV.pptxNEONATAL RESPIRATORY CARE FROM A PHYSIO POV.pptx
NEONATAL RESPIRATORY CARE FROM A PHYSIO POV.pptxHanineHassan2
 
Living Well Every Day: Lyons Wellness Practice | Nurtures Your Complete Health
Living Well Every Day: Lyons Wellness Practice | Nurtures Your Complete HealthLiving Well Every Day: Lyons Wellness Practice | Nurtures Your Complete Health
Living Well Every Day: Lyons Wellness Practice | Nurtures Your Complete HealthLyons Health
 
"ANATOMY AND PHYSIOLOGY OF THE SKIN".pdf
"ANATOMY AND PHYSIOLOGY OF THE SKIN".pdf"ANATOMY AND PHYSIOLOGY OF THE SKIN".pdf
"ANATOMY AND PHYSIOLOGY OF THE SKIN".pdfDolisha Warbi
 
Empathy Is a Stress Response - Choose Compassion instead
Empathy Is a Stress Response - Choose Compassion insteadEmpathy Is a Stress Response - Choose Compassion instead
Empathy Is a Stress Response - Choose Compassion insteadAlex Clapson
 
Identifying Signs of Mental Health Presentation (1).pptx
Identifying Signs of Mental Health Presentation (1).pptxIdentifying Signs of Mental Health Presentation (1).pptx
Identifying Signs of Mental Health Presentation (1).pptxsandhulove46637
 
person with disability and pwd act ppt.pptx
person with disability and pwd act ppt.pptxperson with disability and pwd act ppt.pptx
person with disability and pwd act ppt.pptxMUKESH PADMANABHAN
 
ARTHRITIS.pptx Prepared by monika gopal Tutor
ARTHRITIS.pptx Prepared  by monika gopal TutorARTHRITIS.pptx Prepared  by monika gopal Tutor
ARTHRITIS.pptx Prepared by monika gopal TutorNehaKewat
 

Último (20)

Annual Training
Annual TrainingAnnual Training
Annual Training
 
Artificial Intelligence: Diabetes Management
Artificial Intelligence: Diabetes ManagementArtificial Intelligence: Diabetes Management
Artificial Intelligence: Diabetes Management
 
21 NEMT Trends & Statistics to Know in 2024
21 NEMT Trends & Statistics to Know in 202421 NEMT Trends & Statistics to Know in 2024
21 NEMT Trends & Statistics to Know in 2024
 
Artificial Intelligence in Healthcare: Challenges, Risks, Benefits
Artificial Intelligence in Healthcare: Challenges, Risks, BenefitsArtificial Intelligence in Healthcare: Challenges, Risks, Benefits
Artificial Intelligence in Healthcare: Challenges, Risks, Benefits
 
Anatomy Shelf Notevbhhhhhhhhhhhhhhhs.pdf
Anatomy Shelf Notevbhhhhhhhhhhhhhhhs.pdfAnatomy Shelf Notevbhhhhhhhhhhhhhhhs.pdf
Anatomy Shelf Notevbhhhhhhhhhhhhhhhs.pdf
 
Diseases of the Respiratory System (J00-J99),.pptx
Diseases of the Respiratory System (J00-J99),.pptxDiseases of the Respiratory System (J00-J99),.pptx
Diseases of the Respiratory System (J00-J99),.pptx
 
Three Keys to a Successful Margin: Charges, Costs, and Labor
Three Keys to a Successful Margin: Charges, Costs, and LaborThree Keys to a Successful Margin: Charges, Costs, and Labor
Three Keys to a Successful Margin: Charges, Costs, and Labor
 
ACCA Version of AI & Healthcare: An Overview for the Curious
ACCA Version of AI & Healthcare: An Overview for the CuriousACCA Version of AI & Healthcare: An Overview for the Curious
ACCA Version of AI & Healthcare: An Overview for the Curious
 
Hematinics and Erythropoietin- Pharmacology of Hematinics
Hematinics and Erythropoietin- Pharmacology of HematinicsHematinics and Erythropoietin- Pharmacology of Hematinics
Hematinics and Erythropoietin- Pharmacology of Hematinics
 
Understanding Warts and Moles: Differences, Types, and Common Locations
Understanding Warts and Moles: Differences, Types, and Common LocationsUnderstanding Warts and Moles: Differences, Types, and Common Locations
Understanding Warts and Moles: Differences, Types, and Common Locations
 
CECT NECK NECK ANGIOGRAPHY CAROTID ANGIOGRAPHY
CECT NECK NECK ANGIOGRAPHY CAROTID ANGIOGRAPHYCECT NECK NECK ANGIOGRAPHY CAROTID ANGIOGRAPHY
CECT NECK NECK ANGIOGRAPHY CAROTID ANGIOGRAPHY
 
Toothpaste for bleeding gums and sensitive teeth. Teeth whitening, Mouthwash....
Toothpaste for bleeding gums and sensitive teeth. Teeth whitening, Mouthwash....Toothpaste for bleeding gums and sensitive teeth. Teeth whitening, Mouthwash....
Toothpaste for bleeding gums and sensitive teeth. Teeth whitening, Mouthwash....
 
Painting Rats White Angers Them to No End
Painting Rats White Angers Them to No EndPainting Rats White Angers Them to No End
Painting Rats White Angers Them to No End
 
NEONATAL RESPIRATORY CARE FROM A PHYSIO POV.pptx
NEONATAL RESPIRATORY CARE FROM A PHYSIO POV.pptxNEONATAL RESPIRATORY CARE FROM A PHYSIO POV.pptx
NEONATAL RESPIRATORY CARE FROM A PHYSIO POV.pptx
 
Living Well Every Day: Lyons Wellness Practice | Nurtures Your Complete Health
Living Well Every Day: Lyons Wellness Practice | Nurtures Your Complete HealthLiving Well Every Day: Lyons Wellness Practice | Nurtures Your Complete Health
Living Well Every Day: Lyons Wellness Practice | Nurtures Your Complete Health
 
"ANATOMY AND PHYSIOLOGY OF THE SKIN".pdf
"ANATOMY AND PHYSIOLOGY OF THE SKIN".pdf"ANATOMY AND PHYSIOLOGY OF THE SKIN".pdf
"ANATOMY AND PHYSIOLOGY OF THE SKIN".pdf
 
Empathy Is a Stress Response - Choose Compassion instead
Empathy Is a Stress Response - Choose Compassion insteadEmpathy Is a Stress Response - Choose Compassion instead
Empathy Is a Stress Response - Choose Compassion instead
 
Identifying Signs of Mental Health Presentation (1).pptx
Identifying Signs of Mental Health Presentation (1).pptxIdentifying Signs of Mental Health Presentation (1).pptx
Identifying Signs of Mental Health Presentation (1).pptx
 
person with disability and pwd act ppt.pptx
person with disability and pwd act ppt.pptxperson with disability and pwd act ppt.pptx
person with disability and pwd act ppt.pptx
 
ARTHRITIS.pptx Prepared by monika gopal Tutor
ARTHRITIS.pptx Prepared  by monika gopal TutorARTHRITIS.pptx Prepared  by monika gopal Tutor
ARTHRITIS.pptx Prepared by monika gopal Tutor
 

DIABETIC MACULAR EDEMA, ITS SCREENING IN UAE & MANAGEMENT STRATEGIES.pptx

  • 1. DIABETIC MACULAR EDEMA & ITS MANAGEMENT PRESENTED BY: NIGAR MEHTIYEVA, 10TH SEMESTER, FACULTY OF MEDICINE. UNIVERSITY: TBILISI STATE MEDICAL UNIVERSITY, GEORGIA. Guided by Nino Karanadze, Lions Eye Diabetes Clinic
  • 2. INTRODUCTION • Diabetic macular edema (DME) is a serious complication of diabetes that affects the eyes. • It occurs when the blood vessels in the retina, the part of the eye that senses light and sends images to the brain, become damaged due to high blood sugar levels. • This damage can cause fluid to leak into the macula, the central part of the retina responsible for sharp, detailed vision. • DME can cause vision loss and can make it difficult to read, drive, or recognize faces. • It is a common cause of vision loss in people with diabetes and can occur at any stage of the disease, although it is more common in people with advanced stages of diabetic retinopathy • Early detection and treatment are important in managing DME and preventing vision loss
  • 3. DIABETES PREVALENCE in UAE • The UAE has a high prevalence of diabetes, with rates of 16.3% for adults aged 20-79 years according to IDF statistics in 2019. • A survey from 1999-2000 found a similar rate of 20.0% for those aged 20-64 years using OGTT. • More recent data from the Weqaya screening program in Abu Dhabi for 2008-2010 found age- standardized prevalence rates of 17.6% for diabetes and 27.1% for pre-diabetes. • However, there have been few studies on diabetes prevalence in the UAE since then.
  • 4. • A recent research conducted in the Northern Emirates of the UAE discovered that the rate of diabetes was 25.1% among its citizens. • The prevalence of diabetes was found to be higher in UAE citizens, ranging from 25% as compared to 13-19% in expatriates. • The study also revealed that the rate of diabetes increased with age and reached a maximum of 40% in people over 55 years of age. • The prevalence of impaired fasting glycemia was observed to be 5% in men and 7% in women. • Shockingly, the survey also found that 41% of individuals with diabetes were previously undiagnosed. • Obesity was also found to be common in all ethnic groups in the study
  • 5. RISK FACTORS FOR OBESITY/DIABETES IN UAE • The swift urbanization and socioeconomic advancement in the UAE have resulted in the local population's extensive adoption of a sedentary lifestyle and Westernized diet, contributing to the risk factors for obesity and diabetes. • These risk factors are also linked with increasing waist- hip ratio (WHR), age, systolic blood pressure, and ethnicity. • Additionally, the survey found that co-morbidity with glucose intolerance occurred in 8% of individuals with obesity and with hypertension in 5%
  • 6. OCULAR COMPLICATIONS OF DIABETES: • These conditions include • diabetic retinopathy, • diabetic macular edema, • cataracts, • glaucoma, • poor vision, • diabetes
  • 7. PREVALENCE.. • Diabetic eye diseases make up 2 of the top 5 eye problems affecting UAE patients • Diabetic retinopathy and Diabetic Macular Edema (DME) are two of the top five eye problems affecting UAE patients • One study found prevalence of retinopathy to be 19 per cent in the UAE and was more likely to occur in older males
  • 8. • A collaboration between the Emirates Society of Ophthalmology and a committee consisting of specialized ophthalmologists in Retina, SEHA, Dubai Health Authority, Ministry of Health, and private hospitals in the UAE was formed to work on the Diabetic Macular Edema Management Consensus
  • 9. SCREENING • Bayer ME & Emirates Ophthalmology Society launched "Eyes On" campaign to tackle Diabetic Macular Edema in UAE. • Campaign aims to raise awareness among diabetic patients about the serious implications of DME. • Retinal department at SEHA focuses on conditions at the back of the eye, including diabetic eye screening. • Primary care facilities in UAE offer screening programs for DME. • Patients urged to have their eyes examined as soon as they are diagnosed with diabetes, as Diabetic Retinopathy can already be present in some cases.
  • 10. Introduction on ESO • ESO has taken on the responsibility of overseeing and organizing scientific training, conferences, and events while also collaborating with health organizations. • It is considered the leading Society for Ophthalmology in the GCC area, not just in the UAE. • The society aims to promote Continuous Professional Development, facilitate the exchange of scientific information, and encourage research and development in Ophthalmology.
  • 11. • ESO has developed these guidelines with the objective of offering clinical recommendations that are based on evidence, for the optimal management of various aspects of diabetic eye disease. • The guidelines have been created with a specific focus on the management of Diabetic Macular Edema, and have been designed to address cases of retinopathy that pose a serious risk to vision.
  • 12. Treatment Pre-requisites • It is recommended to check Visual Acuity (VA) before initiation of treatment • recommended to check intraocular pressure (IOP) before initiation of treatment • OCT is recommended before the initiation of treatment, • Ocular fundus exam is recommended • Fundus Fluorescein Angiography (FFA)
  • 13. WHEN SHOULD WE TREAT? • The purpose of treating DME is to enhance vision when it is impaired, preserve existing vision, and prevent any structural harm to the macula. • It is essential to conduct a thorough evaluation of the macula's structure and function to achieve this goal • Conditions which are needed to initiate treatment: • Best Corrected Visual Acuity (BCVA) of 20/30 or below, and/or the presence of DME features as observed on OCT, with a Central Retinal Thickness (CRT) of 300 microns or more (≥300 μm). • Patients experiencing symptoms with vision better than 20/25(13) and /or CRT<300 μm(12,13) with OCT features indicative of center-involving macular edema should be treated.
  • 14. General Guidance in DME Management • Good control of Diabetes Mellitus and HbA1c, arterial hypertension, dyslipidemia, and quitting smoking is crucial for managing DME. • Achieving a normal BMI through weight loss is important • Manage renal impairment, sleep apnea, and other relevant conditions in consultation with a diabetologist • Fenofibrate and statin can be recommended to the family physicians / endocrinologists as anti-dyslipidemia medication • Investigate other potential ocular causes of decreased vision. • Monitor for any new medications or changes in medication that could exacerbate macular edema, such as Glitazones
  • 15. • Conduct FFA/OCTA to evaluate macular ischemia in case of no improvement in visual acuity • Use anti-VEGF injections or Dexamethasone Implant to reduce macular thickness • Discuss all ophthalmic treatment options with the patient • Improve compliance and set realistic expectations • All ophthalmic treatment options should be discussed with the patient for better compliance and expectations
  • 16. Tx Recommendation for Non-Centre Involving DME • Observation may be the initial approach for Non-Center Involving DME • Anti-VEGF therapy or FFA-guided focal laser may be recommended if there is progression towards the center • Avoid treatment closer than 300-500 μm from the center of the macula • Focal Laser should only be performed by a retina specialist in special circumstances
  • 17. Treatment Recommendation for Centre Involving DME • Anti-VEGF therapy is the first-line treatment option for Centre-Involving DME (CI-DME) • Steroid implant (Dexamethasone implant) may be used as a first-line treatment if anti-VEGF therapy is not recommended or if the patient is poorly compliant • Regular follow-up is required to monitor intraocular pressure (IOP) • Dexamethasone implant may be suggested for vitrectomized, pseudophakic, or chronic DME patients • Treatment algorithms may vary based on patient and physician preferences.
  • 18. • Fixed, pro re nata (PRN), and treat-and-extend dosing strategies can be considered for treating DME • All patients treated with anti-VEGF should have a loading dose of 3-5 injections • Estimated number of injections is 8-9 in the first year and 5-6 in the second year, including the loading dose • Dosing strategies based on VA and OCT response
  • 19. Anti-VEGF Contraindications • Avoid anti-VEGF treatment for at least 3 months after myocardial infarction or stroke • Anti-VEGF treatment is not recommended during pregnancy or breastfeeding • Steroid can be considered as first-line treatment in pregnancy or breastfeeding • Intravitreal therapy for DME should be deferred in cases of active infection
  • 20. Relapsing DME(Edema After 1Year) • If a patient experiences relapsing DME and there is clear evidence of a response to a previous treatment, the same treatment can be repeated. • However, if there is no response, the patient should be treated as a new case and any available treatment option, such as anti-VEGF or a Dexamethasone implant, should be considered.
  • 21. Refractory DME • Refractory DME is defined as DME not responding to a full course of anti- VEGF agents and steroid implants. • In such cases, we can consider ; • a combination therapy with anti-VEGF and steroids • or • referral to a retina surgeon for vitrectomy if OCT confirms ERM or VMT.
  • 22. Steroid Implant • Dexamethasone implant injections recommended: 3-4 within 12 months • If good response and infrequent recurrence, continue with Dexamethasone implant • Effect of Dexamethasone implant peaks at 6-8 weeks and lasts up to 4 months • If frequent fluid recurrence, switch to Anti-VEGF after discussing with patient • If patient prefers not to receive implant every 4 months, consider switching to Fluocinolone implant.
  • 23. Contraindications of Dexamethasone and fluocinolone acetonide intravitreal implants • patients with active or suspected ocular or periocular infection, • advanced glaucoma requiring more than three medications, • non-intact posterior capsule (excluding YAG capsulotomy), • aphakia, • or hypersensitivity to Dexamethasone implant • or fluocinolone acetonide intravitreal implant should not receive these treatments.
  • 24. DME and PDR • Initially assess VA, and do a fully dilated fundus exam. • Anti-VEGF agents are the first-line treatment for centre- involving DME. • Anti-VEGF treatment or pan retinal photocoagulation (PRP) can be considered for non-centre involving DME and PDR • Combination of both treatments can be used for PDR • Anti-VEGF injections can be continued for DME after PDR treatment.
  • 25. Diabetic Macular Edema and Pregnancy • Control blood glucose and use laser treatment as first-line options for managing DME during pregnancy • Avoid anti-VEGF treatment for DME during pregnancy • Intravitreal Dexamethasone implant can be considered for severe DME • Laser treatment is a viable option for non-centre-involving Macular edema • Treatment can be postponed until after delivery if feasible • If treatment is offered during pregnancy, it should be done only in the second or third trimesters • Discuss potential risks of treatment with the patient, including elevated intraocular pressure, cataract development, and rare risk of fetal harm.